Peptibodies: A flexible alternative format to antibodies

The development of romiplostim for patients with immune thrombocytopenia

(2011) Graham Molineux   Annals of the New York Academy of Sciences

Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor

(2010) Michael P. Hall et al.   AAPS Journal

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

(2010) David J. Kuter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels

(2009) Beverly L. Falcón et al.   AMERICAN JOURNAL OF PATHOLOGY

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

(2009) Roland E. Kontermann   BIODRUGS

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Nerve Growth Factor in Rheumatic Diseases

(2009) Matthias F. Seidel et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET